
ANT-1 Rabbit pAb

Catalog Number: bs-6794R

Target Protein: ANT-1

Concentration: 1mg/ml

Form: Liquid

Host: Rabbit

Clonality: Polyclonal

Isotype: IgG

Applications: IHC-P (1:100-500), IHC-F (1:100-500), IF (1:100-500)

Reactivity: Human (predicted: Mouse, Rat, Rabbit, Pig, Sheep, Cow, Dog)

Predicted MW: 33 kDa

Entrez Gene: 291

Swiss Prot: P12235

Source: KLH conjugated synthetic peptide derived from human ANT-1: 31-130/298.


Purification: affinity purified by Protein A

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: Defects in SLC25A4 are a cause of progressive external ophthalmoplegia with mitochondrial DNA deletions autosomal dominant type 2 (PEOA2) [MIM:609283]. Progressive external ophthalmoplegia is characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

VALIDATION IMAGES



Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37°C for 20 min; Incubation: Anti-ANT-1 Polyclonal Antibody, Unconjugated(bs-6794R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining